CPT code 54235 denotes an intracavernosal pharmacologic injection procedure used to treat erectile dysfunction by administering agents such as papaverine, phentolamine, or prostaglandin E1 into the corpora cavernosa. Nationally, this code captures a common outpatient therapeutic intervention for patients who have not responded to oral therapies or require diagnostic/therapeutic intracavernosal testing. Understanding billing and coverage patterns for this service matters because it affects access to specialty urologic care and informs payment policy for office- and ambulatory-based procedures.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for when the procedure is used, typical sites of service, and how the code is defined for billing purposes. The publication provides benchmarks where available, notes on payer coverage considerations, and policy-relevant updates impacting coding and claims processing. Data not available in the input are identified clearly. This summary is intended to support revenue cycle, compliance, and clinical teams seeking a concise reference to the clinical intent and billing identity of CPT code 54235.